HN2008001104A - Compuestos para anticuerpos de dickpf-1 y70-4 - Google Patents
Compuestos para anticuerpos de dickpf-1 y70-4Info
- Publication number
- HN2008001104A HN2008001104A HN2008001104A HN2008001104A HN2008001104A HN 2008001104 A HN2008001104 A HN 2008001104A HN 2008001104 A HN2008001104 A HN 2008001104A HN 2008001104 A HN2008001104 A HN 2008001104A HN 2008001104 A HN2008001104 A HN 2008001104A
- Authority
- HN
- Honduras
- Prior art keywords
- dickpf
- antibody compounds
- objective
- cell
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Child & Adolescent Psychology (AREA)
Abstract
SE PROPORCIONA ANTICUERPOS Y FRAGMENTOS QUE SE ENLAZAN CON EL OBJETIVO DE PROTEINA DICKKOPF(DKK1) ASI COMO METODOS DE USO Y KITS , PARA EL TRATAMIENTO DE UNA CELULA OBJETIVO, EN PARTICULAR UNA CELULA ASOCIADA CON UNA CONDICION OSTEOLITICA
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75921606P | 2006-01-13 | 2006-01-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
HN2008001104A true HN2008001104A (es) | 2011-06-08 |
Family
ID=38288117
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HN2008001104A HN2008001104A (es) | 2006-01-13 | 2008-07-14 | Compuestos para anticuerpos de dickpf-1 y70-4 |
Country Status (31)
Country | Link |
---|---|
US (3) | US8673306B2 (es) |
EP (1) | EP1976594B1 (es) |
JP (2) | JP5552233B2 (es) |
KR (1) | KR101413785B1 (es) |
CN (1) | CN101400406B (es) |
AR (1) | AR060017A1 (es) |
AU (1) | AU2007207787B2 (es) |
BR (1) | BRPI0706524A2 (es) |
CA (1) | CA2636579A1 (es) |
CR (1) | CR10128A (es) |
CU (1) | CU23871B1 (es) |
EA (1) | EA015538B1 (es) |
EC (1) | ECSP088618A (es) |
GE (1) | GEP20125476B (es) |
HK (1) | HK1121420A1 (es) |
HN (1) | HN2008001104A (es) |
IL (1) | IL192631A (es) |
MA (1) | MA30158B1 (es) |
ME (2) | MEP1308A (es) |
MY (1) | MY153573A (es) |
NO (1) | NO20083477L (es) |
NZ (1) | NZ569555A (es) |
PE (2) | PE20120816A1 (es) |
SG (1) | SG169327A1 (es) |
SM (1) | SMP200800042B (es) |
SV (1) | SV2008002980A (es) |
TN (1) | TNSN08297A1 (es) |
TW (1) | TWI432450B (es) |
UA (1) | UA101944C2 (es) |
WO (1) | WO2007084344A2 (es) |
ZA (1) | ZA200805743B (es) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
KR20110117601A (ko) * | 2010-04-21 | 2011-10-27 | 주식회사 테라젠이텍스 | 혈관신생과 연관된 화합물을 탐색하는 방법 |
US8450274B2 (en) | 2006-05-24 | 2013-05-28 | Theragenetex Co., Ltd. | DKK2 protein and use thereof |
JP2009065938A (ja) * | 2007-09-14 | 2009-04-02 | Matsumoto Shika Univ | タンパク質、破骨細胞分化阻害剤、炎症性骨破壊治療薬、遺伝子、組み替えベクター、及びタンパク質の製造方法 |
TWI489993B (zh) | 2007-10-12 | 2015-07-01 | Novartis Ag | 骨硬化素(sclerostin)抗體組合物及使用方法 |
JP5320730B2 (ja) * | 2007-12-26 | 2013-10-23 | Jnc株式会社 | 発光基質水溶液およびその製造方法 |
US8551789B2 (en) | 2010-04-01 | 2013-10-08 | OncoMed Pharmaceuticals | Frizzled-binding agents and their use in screening for WNT inhibitors |
JP5792621B2 (ja) | 2008-09-26 | 2015-10-14 | オンコメッド ファーマシューティカルズ インコーポレイテッド | frizzled結合剤およびその使用 |
WO2010100200A2 (en) * | 2009-03-05 | 2010-09-10 | Novartis Ag | Lyophilised antibody formulation |
AR075989A1 (es) * | 2009-04-10 | 2011-05-11 | Lilly Co Eli | Anticuerpo dkk -1 (dickkopf-1) humano disenado por ingenieria |
WO2010129752A1 (en) * | 2009-05-07 | 2010-11-11 | Novartis Ag | Compositions and methods of use for binding molecules to dickkopf-1 or dickkopf-4 or both |
CA2761696A1 (en) | 2009-05-12 | 2010-11-18 | Pfizer Inc. | Blocking anti-dkk-1 antibodies and their uses |
WO2010130832A2 (en) * | 2009-05-15 | 2010-11-18 | Ablynx N.V. | Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions |
WO2011053665A1 (en) * | 2009-10-30 | 2011-05-05 | Merck Sharp & Dohme Corp. | Pcsk9 immunoassay |
TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Wnt拮抗劑及治療和篩選方法 |
SG10201507722QA (en) * | 2010-03-11 | 2015-10-29 | Rinat Neuroscience Corp | ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING |
ES2863626T3 (es) * | 2010-10-27 | 2021-10-11 | Amgen Inc | Anticuerpos DKK1 y métodos de uso |
EP2670435B1 (en) * | 2011-02-01 | 2017-08-23 | The University of Hong Kong | Use of anti-dkk1 monoclonal antibody for treatment of liver cancer |
US9133272B2 (en) | 2011-03-01 | 2015-09-15 | Amgen Inc. | Bispecific binding agents |
CN103487581A (zh) * | 2012-06-08 | 2014-01-01 | 上海市肿瘤研究所 | 血清dkk1在制备甲胎蛋白阴性肝细胞癌的诊断试剂中的用途 |
CN103472226A (zh) * | 2012-06-08 | 2013-12-25 | 上海市肿瘤研究所 | 血清dkk1在制备早期肝细胞癌或小肝细胞癌的诊断试剂中的用途 |
UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
WO2014121196A1 (en) * | 2013-02-04 | 2014-08-07 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a wnt pathway inhibitor |
CN103083686B (zh) * | 2013-02-18 | 2014-09-10 | 上海交通大学医学院附属仁济医院 | Dkk4基因及其编码蛋白在制备药物中的应用 |
WO2014144817A2 (en) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Inhibitory polypeptides specific to wnt inhibitors |
ES2903029T3 (es) * | 2014-07-03 | 2022-03-30 | Univ Yale | La inhibición de DICKKOPF2 (DKK2) suprime la formación de tumores |
DE102016206820B4 (de) | 2015-04-22 | 2017-07-27 | BSH Hausgeräte GmbH | Weiterentwicklung eines Induktionswasserkochers, einer Kaffeemaschine und einer Suppenmaschine |
RS62151B1 (sr) * | 2015-08-07 | 2021-08-31 | Alx Oncology Inc | Konstrukti koji sadrže sirp-alfa domen ili njegovu varijantu |
CN105203773A (zh) * | 2015-09-28 | 2015-12-30 | 成都博奥新景医学科技有限公司 | 一种人Dickkopf-1蛋白(DKK-1)定量检测试剂盒 |
WO2017074774A1 (en) * | 2015-10-28 | 2017-05-04 | Yale University | Humanized anti-dkk2 antibody and uses thereof |
RU2656160C2 (ru) * | 2016-08-17 | 2018-05-31 | Закрытое Акционерное Общество "Биокад" | Антитело или его антигенсвязывающий фрагмент, способный связываться с рецептором интерлейкина-6 человека |
MX2019004940A (es) * | 2016-10-26 | 2019-09-26 | Leap Therapeutics Inc | Uso de beta-catenina como un biomarcador para el tratamiento de canceres que usan el anticuerpo anti-dkk-1. |
KR20180123989A (ko) * | 2017-05-10 | 2018-11-20 | 주식회사 굳티셀 | 조절 t 세포에 특이적으로 존재하는 dkk1 단백질 및 그 용도 |
WO2020149644A1 (ko) * | 2019-01-15 | 2020-07-23 | (주)바이오니아 | Dkk1 유전자를 표적으로 하는 이중나선 올리고뉴클레오티드, 이를 포함하는 구조체 및 이를 포함하는 탈모 예방 또는 발모용 조성물 |
US20220089707A1 (en) * | 2019-02-01 | 2022-03-24 | Board Of Regents, The University Of Texas System | Monoclonal antibodies against mhc-bound human dickkopf-1 peptides and uses thereof |
US11613564B2 (en) | 2019-05-31 | 2023-03-28 | ALX Oncology Inc. | Methods of treating cancer |
CN112121147B (zh) * | 2019-06-24 | 2023-07-04 | 中国人民解放军海军特色医学中心 | 多肽在治疗或预防骨髓瘤药物中的应用、多肽、核酸、药物及重组表达载体 |
CN111632147A (zh) * | 2020-06-07 | 2020-09-08 | 重庆医科大学 | 骨细胞Wnt激活剂在制备骨折加速愈合、防治骨不连及不运动或失重骨丢失药物中的应用 |
KR102494042B1 (ko) * | 2020-11-20 | 2023-02-07 | 주식회사 하울바이오 | 인간모유두세포의 성장을 촉진하는 항-dkk-1 항체 및 이의 용도 |
CN112592402B (zh) * | 2020-12-02 | 2022-04-26 | 杭州奕安济世生物药业有限公司 | 抗dkk2抗体、包含该抗dkk2抗体的组合物及其用途 |
WO2022140670A2 (en) * | 2020-12-23 | 2022-06-30 | Phenomic Ai | Anti-activin antibodies and methods of using the same |
CN117916377A (zh) * | 2021-09-26 | 2024-04-19 | 安沛治疗有限公司 | 针对dkk1的适体及其用途 |
WO2023143444A1 (zh) * | 2022-01-28 | 2023-08-03 | 上海君实生物医药科技股份有限公司 | 抗dkk1抗体、其药物组合物及用途 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5597710A (en) | 1994-03-10 | 1997-01-28 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-4 |
US7057017B2 (en) | 1997-04-16 | 2006-06-06 | Millennium Pharmaceuticals, Inc. | Human dickkopf-related protein and nucleic acid molecules and uses therefor |
DK0975755T3 (da) | 1997-04-16 | 2007-06-11 | Millennium Pharm Inc | CRSP-protein (cysteinrige udskilte proteiner), nukleinsyremolekyler der koder herfor samt anvendelser deraf |
DE19747418C1 (de) | 1997-10-27 | 1999-07-15 | Deutsches Krebsforsch | Inhibitor-Protein des wnt-Signalwegs |
US7446181B2 (en) | 1998-01-15 | 2008-11-04 | Millennium Pharmaceuticals, Inc. | Antibodies that bind human Dickkopf-1 proteins |
WO2000006714A1 (en) | 1998-07-31 | 2000-02-10 | Eli Lilly And Company | DDKh-3 NUCLEIC ACIDS, POLYPEPTIDES, VECTORS, HOST CELLS, METHODS AND USES THEREOF |
US7071304B2 (en) | 1998-09-01 | 2006-07-04 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US6344541B1 (en) | 1998-09-25 | 2002-02-05 | Amgen Inc. | DKR polypeptides |
EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
EP1399483B1 (en) | 2001-01-05 | 2010-04-14 | Pfizer Inc. | Antibodies to insulin-like growth factor i receptor |
CA2438245A1 (en) * | 2001-02-16 | 2002-08-29 | Genentech, Inc. | Treatment involving dkk-1 or antagonists thereof |
ATE484522T1 (de) * | 2001-04-24 | 2010-10-15 | Bayer Corp | Menschliche antikörper gegen timp-1 |
CA2466483A1 (en) | 2001-11-07 | 2003-07-03 | John D. Shaughnessy | Diagnosis prognosis and identification of potential therapeutic targets of multiple myeloma based on gene expression profiling |
AR038568A1 (es) | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | Anticuerpos anti-a beta y su uso |
ATE500837T1 (de) | 2002-12-05 | 2011-03-15 | Univ Arkansas | Molekulare determinanten des multiplen myeloms und deren verwendung |
US20050084494A1 (en) * | 2003-05-21 | 2005-04-21 | Darwin Prockop | Inhibitors of Dkk-1 |
WO2006017538A2 (en) | 2004-08-03 | 2006-02-16 | Dyax Corp. | Hk1-binding proteins |
WO2006015373A2 (en) * | 2004-08-04 | 2006-02-09 | Amgen Inc | Antibodies to dkk-1 |
GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
CN101146909A (zh) | 2005-03-25 | 2008-03-19 | 格黎卡特生物技术股份公司 | 针对MCSP的并且具有增加的Fc受体结合亲和性和效应子功能的抗原结合分子 |
CA2627075A1 (en) * | 2005-11-14 | 2007-05-18 | Bioren, Inc. | Antibody ultrahumanization by predicted mature cdr blasting and cohort library generation and screening |
-
2007
- 2007-01-11 AR ARP070100119A patent/AR060017A1/es unknown
- 2007-01-12 AU AU2007207787A patent/AU2007207787B2/en not_active Ceased
- 2007-01-12 ME MEP-13/08A patent/MEP1308A/xx unknown
- 2007-01-12 UA UAA200808758A patent/UA101944C2/ru unknown
- 2007-01-12 EA EA200801679A patent/EA015538B1/ru not_active IP Right Cessation
- 2007-01-12 PE PE2011001865A patent/PE20120816A1/es not_active Application Discontinuation
- 2007-01-12 KR KR1020087019725A patent/KR101413785B1/ko not_active IP Right Cessation
- 2007-01-12 SG SG201100297-9A patent/SG169327A1/en unknown
- 2007-01-12 CN CN200780009135.2A patent/CN101400406B/zh active Active
- 2007-01-12 ME MEP-2008-13A patent/ME00010B/me unknown
- 2007-01-12 PE PE2007000031A patent/PE20071239A1/es not_active Application Discontinuation
- 2007-01-12 US US12/160,875 patent/US8673306B2/en active Active
- 2007-01-12 WO PCT/US2007/000777 patent/WO2007084344A2/en active Application Filing
- 2007-01-12 BR BRPI0706524-8A patent/BRPI0706524A2/pt not_active IP Right Cessation
- 2007-01-12 SM SM200800042T patent/SMP200800042B/it unknown
- 2007-01-12 GE GEAP200710809A patent/GEP20125476B/en unknown
- 2007-01-12 NZ NZ569555A patent/NZ569555A/en not_active IP Right Cessation
- 2007-01-12 CA CA002636579A patent/CA2636579A1/en not_active Abandoned
- 2007-01-12 MY MYPI20082536A patent/MY153573A/en unknown
- 2007-01-12 JP JP2008550418A patent/JP5552233B2/ja not_active Expired - Fee Related
- 2007-01-12 TW TW096101263A patent/TWI432450B/zh not_active IP Right Cessation
- 2007-01-12 EP EP20070709712 patent/EP1976594B1/en active Active
-
2008
- 2008-07-01 ZA ZA200805743A patent/ZA200805743B/xx unknown
- 2008-07-03 IL IL192631A patent/IL192631A/en not_active IP Right Cessation
- 2008-07-04 CR CR10128A patent/CR10128A/es unknown
- 2008-07-04 CU CU20080133A patent/CU23871B1/es not_active IP Right Cessation
- 2008-07-11 TN TNP2008000297A patent/TNSN08297A1/en unknown
- 2008-07-11 MA MA31110A patent/MA30158B1/fr unknown
- 2008-07-11 EC EC2008008618A patent/ECSP088618A/es unknown
- 2008-07-11 SV SV2008002980A patent/SV2008002980A/es unknown
- 2008-07-14 HN HN2008001104A patent/HN2008001104A/es unknown
- 2008-08-11 NO NO20083477A patent/NO20083477L/no not_active Application Discontinuation
-
2009
- 2009-02-25 HK HK09101770.5A patent/HK1121420A1/xx not_active IP Right Cessation
-
2012
- 2012-12-17 JP JP2012274999A patent/JP2013099334A/ja active Pending
-
2014
- 2014-01-24 US US14/163,230 patent/US20140341901A1/en not_active Abandoned
- 2014-02-12 US US14/178,892 patent/US9296813B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HN2008001104A (es) | Compuestos para anticuerpos de dickpf-1 y70-4 | |
AR060241A1 (es) | Composiciones y metodos de uso para anticuerpos de c-met | |
CO6680656A2 (es) | Anticuerpos para metaloproteinasa -9 de matriz | |
BRPI1013688A8 (pt) | Proteínas de ligação de il-17. | |
CU23809A3 (es) | Anticuerpo específico prlr | |
BR112012031071A2 (pt) | 8-proteínas de ligação à il-1 | |
HN2005029978A (es) | Formulaciones | |
CL2007003622A1 (es) | Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales. | |
AR076655A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b | |
CL2012000631A1 (es) | Anticuerpo capaz de unirse específicamente a un amiloide beta, que comprende los 3 cdrs de cadena liviana (sec nº21/22/23) y los 3 cdrs de cadena pesada (sec nº24/25/26); polinucleótido y línea celular que lo codifican; composición que lo comprende; método de producción y diagnostico; kit; y su uso terapéutico. | |
BR112015014751A2 (pt) | anticorpos anti-tau humanos | |
WO2010011944A3 (en) | Protein screeing methods | |
NI201200014A (es) | Anticuerpos humanos de alta afinidad para la angiopoyetina - 2 humana | |
CL2012002741A1 (es) | Metodo para determinar en una muestra de sangre la presencia de vitamina d libre; inmunoensayo para detrminar presencia de vitamina d libre en sangre; kit para efectuar inmunoensayo. | |
CU23978B1 (es) | Composiciones para anticuerpos que se dirigen a la proteína de complemento c5 | |
EA201170242A1 (ru) | Модифицированные бычьи полипептиды g-csf и их применение | |
BR112012009846B8 (pt) | método in vitro e kit para detecção de um anticorpo antifármaco de isotipo ige, e uso de um anticorpo antifármaco de isotipo ige no tratamento de distúrbio mediado por ige | |
MX2010000680A (es) | Materiales y metodos para selección de esperma sexual. | |
CY1113309T1 (el) | Συνθεσεις και μεθοδοι χρησιμοποιωντας αντι-cs1 αντισωματα για να θεραπευεται πολλαπλο μυελωμα | |
AR060440A1 (es) | Agonistas receptores de eritropoietina | |
ATE426046T1 (de) | Stoffliche nutzung von biogas | |
BRPI0504469B8 (pt) | composições cicatrizantes | |
CL2008001275A1 (es) | Procedimiento de seleccion de moleculas que comprende ponerlas en contacto con embriones vivos de pez cebra y seleccionar aquellas que afectan la migracion del primordio en la linea lateral en los embriones de pez cebra. |